Keryx Biopharmaceuticals Inc
KERX
KERX was delisted on the 12th of December, 2018.
140 hedge funds and large institutions have $1.04B invested in Keryx Biopharmaceuticals Inc in 2014 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 51 increasing their positions, 42 reducing their positions, and 18 closing their positions.
28% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 18
21% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 42
4% more funds holding
Funds holding: 135 → 140 (+5)
0% more capital invested
Capital invested by funds: $1.04B → $1.04B (+$2.21M)
22% less call options, than puts
Call options by funds: $29.7M | Put options by funds: $37.9M
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
+$119M |
| 2 |
Franklin Resources
San Mateo,
California
|
+$30M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$21.9M |
| 4 |
ORI
Oak Ridge Investments
Chicago,
Illinois
|
+$18.1M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$15.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$40.6M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$19.2M |
| 3 |
HCM
Harvey Capital Management
Palm Beach,
Florida
|
-$14.3M |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
-$11.8M |
| 5 |
VM
VHCP Management
New York
|
-$10.8M |
KERX Hedge Fund Activity: Q3 2014 in Review
140 of the 3,448 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q3 2014, worth a combined $1.04B — up 0.21% from $1.04B a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new KERX positions and 18 closed out — a net gain of 5 holders — while 51 added to existing stakes and 42 trimmed.
The largest buyer was Baupost Group, adding an estimated $119M. The largest seller was Deerfield Management, cutting an estimated $40.6M.
- 140 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q3 2014, up from 135 in Q2 2014.
- Funds reported $1.04B of Keryx Biopharmaceuticals Inc stock for Q3 2014, up 0.21% quarter-over-quarter.
- 23 funds opened new Keryx Biopharmaceuticals Inc positions in Q3 2014 and 18 closed out, a net change of +5 holders.
- The largest Keryx Biopharmaceuticals Inc buyer in Q3 2014 was Baupost Group, an estimated $119M added.
- The largest Keryx Biopharmaceuticals Inc seller in Q3 2014 was Deerfield Management, an estimated $40.6M sold.
Based on aggregated 13F filings for Q3 2014.